Janux Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 64
- Market Cap
- $2.3B
- Website
- http://www.januxrx.com
- Introduction
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerRenal Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckColorectal CarcinomaSmall Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple-negative Breast Cancer
- Interventions
- Drug: JANX008
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Janux Therapeutics
- Target Recruit Count
- 130
- Registration Number
- NCT05783622
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸University of California San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Phase 1
Recruiting
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate CancerCastration Resistant Prostatic Cancer
- Interventions
- Biological: JANX007
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Janux Therapeutics
- Target Recruit Count
- 105
- Registration Number
- NCT05519449
- Locations
- 🇺🇸
UCLA Department of Medicine, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath